Gordon Srkalovic, MD
Hematology & Oncology · Lansing, MINPI 1780783282
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $131,591 of the $166,869 with a category attached, or 78.9%. 16 manufacturers reported payments, led by EUSA Pharma (US) LLC at 24.2% of the total. Reporting peaked in 2019 at $90,662 and has fallen 98.1% since, to $1,750 in 2025. Among hematology & oncology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 168 payments — averaging $993.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EUSA Pharma (US) LLC$40K
- Johnson & Johnson$39K
- Takeda Pharmaceuticals U.S.A., Inc.$33K
- Recordati_rare_diseases_inc.$33K
- Foundation Medicine, Inc.$19K
- AstraZeneca$2K
- plus $376 from 10 others
Across 105 payments — averaging $5002.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$214K
- Pfizer$95K
- Eli Lilly$41K
- Ipsen Bioscience Inc.$40K
- AbbVie$40K
- Janssen Research & Development, LLC$34K
- plus $61K from 8 others
What the payments were for
- Consulting fees$11,7587%
- Speaking & faculty fees$131,59179%
- Travel & lodging$19,96912%
- Food & beverage$3,4072%
- Education$1440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EUSA Pharma (US) LLC | 45 | $40,445 |
| Johnson & Johnson | 37 | $38,557 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $33,061 |
| Recordati_rare_diseases_inc. | 21 | $32,955 |
| Foundation Medicine, Inc. | 25 | $19,421 |
| AstraZeneca | 1 | $2,055 |
| Astellas Pharma US Inc | 1 | $99 |
| Bristol Myers Squibb | 4 | $82 |
| AbbVie | 2 | $55 |
| Novartis | 3 | $50 |
| Pfizer | 1 | $17 |
| Amgen | 1 | $15 |
| Eisai Inc. | 1 | $15 |
| Gilead | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Karyopharm Therapeutics Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Sylvant$72,452
- DARZALEX$37,573
- NINLARO$28,179
- FOUNDATIONONE CDX$19,055
- FOUNDATIONFOCUS$18,169
- FOUNDATIONONE HEME$18,169
- FOUNDATIONONE$18,169
- FOUNDATIONACT$10,645
- FOUNDATIONONE LIQUID$6,800
- IMFINZI$2,055
- FOUNDATIONONE LIQUID CDX$724
- IMBRUVICA$113
How this compares
$166,869 in reported general payments places this provider in the 95th percentile of 282 hematology & oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 33 | $790,609 |
| Lenalidomide | 55 | $773,469 |
| RevlimidLenalidomide | 39 | $696,168 |
| ImbruvicaIbrutinib | 41 | $692,725 |
| BrukinsaZanubrutinib | 25 | $362,794 |
| XtandiEnzalutamide | 35 | $349,739 |
| CalquenceAcalabrutinib Maleate | 24 | $334,109 |
| TabrectaCapmatinib Hydrochloride | 13 | $278,174 |
| InlytaAxitinib | 14 | $137,958 |
| BosulifBosutinib | 13 | $133,747 |
| Abiraterone Acetate | 33 | $115,017 |
| CreonLipase/Protease/Amylase | 23 | $92,103 |
| XareltoRivaroxaban | 39 | $51,838 |
| EliquisApixaban | 31 | $29,962 |
| Imatinib Mesylate | 33 | $22,525 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $14 | $790,60933 claims |
| Bristol Myers SquibbRevlimid | $82 | $696,16839 claims |
| Astellas Pharma US IncXtandi | $99 | $349,73935 claims |
| AstraZenecaCalquence | $2,055 | $334,10924 claims |
| PfizerInlyta, Bosulif, Eliquis | $17 | $301,66658 claims |
| NovartisTabrecta | $50 | $278,17413 claims |
| AbbVieCreon, Viberzi | $55 | $109,85935 claims |
| Johnson & JohnsonXarelto | $38,557 | $51,83839 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 282 hematology & oncology providers in Michigan.
Other hematology & oncology in Lansing
- Brittani ThomasLansing$7K
- Faisal MusaDearborn$976K
- Mohammed Al HallakDetroit$644K
- Daniel LebovicGrosse Pointe Woods$352K
- Sreenivasa ChandanaGrand Rapids$305K
- Mohammad ChistiTroy$180K
- Jeffrey ZonderDetroit$88K
- Madan AroraFlint$84K
- Hadeel AssadDetroit$80K
- Andrew MuskovitzSouthfield$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.